A positron emission tomography (PET) study of cerebral dopamine D 2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian)

Psychopharmacology

Volumn 180, Issue 2, 2005, Pages 377-384

  Hode Y ^a   Reimold, M ^b   Demazieres A ^a   Reischl, G ^c   Bayle, F ^d   Nuss, P ^e   Hameg, A ^f   Dib, M ^f   Macher, J P ^a  

^a FORENAP   (France)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d INSERM   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f SANOFI   (France)

Author keywords

11C N methyl spiperone; 11C Raclopride; Cyamemazine; Dopamine D2; Positron emission tomography (PET); Receptor occupancy; Serotonin 5 HT2A

Indexed keywords

3 METHYLSPIPERONE C 11; CARBON 11; CYAMEMAZINE; DOPAMINE 2 RECEPTOR; PROLACTIN; RACLOPRIDE; RACLOPRIDE C 11; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYNDROME; FRONTAL CORTEX; HUMAN; MALE; PERSONALITY DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RECEPTOR OCCUPANCY; SAMPLE SIZE; STRIATE CORTEX;

ADULT; BRAIN; HUMANS; MALE; MIDDLE AGED; PHENOTHIAZINES; POSITRON-EMISSION TOMOGRAPHY; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2;

EID: 21344455083     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2172-z     Document Type: Article

References (49)

1. 11C-raclopride. Arch Neurol 50(5):474-480
2. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
3. Bigliani V, Pilowski LS (1999) In vivo neuropharmacology of schizophrenia. Br J Psychiatry 194(suppl 38):23-33
4. Bourin M, Nic Dhonnchadha BA, Colombel MC, Dib M, Hascoët M (2001) Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 124:87-95
5. Bourin M, Dailly E, Hameg A, Dib M, Garay RP, Hascoët M (2004a) A study of the antipsychotic action of cyamemazine in mouse behavioral models. Collegium Internationale Neuro-Psychopharmacologicum/XXIVth CINP Congress. Paris, June 20-24, 2004
6. Bourin M, Dailly E, Hascoët M (2004b). Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev 10(3):219-229
7. Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F et al (2002) Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 28(2):129-138
8. Daniel D (1995) Metabolism of psychotropic drugs: pharmacological and clinical relevance. Pol J Pharmacol 47:367-379
9. Dannals RF, Ravert HT, Wilson AA, Wagner HN (1986) An improved synthesis of (3-N-[11C]methyl)spiperone. Appl Radiat Isotopes 37:433-434
10. 2 receptor ligands. J Labelled Compd Radiopharm 24:931-940
11. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708
12. 2 dopamine receptors in neuroleptic naive schizophrenic patients. Arch Gen Psychiatry 47:213-219
13. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
14. 2 receptor occupancy in clozapine treated patients. J Clin Psychiatry 55:9(suppl B):67-69
15. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lépine JP, Bégaud B (2000) Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. J Clin Pharmacol 49:80-86
16. Gury C, Berchot F, Fabre C, Surugue J, Welcomme N (2000) Analysis of neuroleptics prescriptions in five specialized hospitals: comparison between hospital prescriptions and discharge prescriptions. Inf Psychiatr 8:954-963
17. Gury C, Simo E, Fabre C, Surugue J, Welcomme N (2004) Prescriptions of antipsychotic drugs in five specialized hospital centers in 2002: comparative analysis with 1998. Collegium Internationale Neuro-Psychopharmacologicum/XXIVth CINP Congress. Paris, June 20-24, 2004
18. Guy W (1976) Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, ECDEU: National Institutes of Health, pp 218-222
19. 2 dopamine receptors. J Nucl Med 36:1275-1281
20. Hameg A, Bayle F, Nuss P, Dupuis P, Garay PR, Dib M (2003) Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine versus serotonin receptor subtypes. Biochem Pharmacol 7497:1-6
21. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
22. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wagelius U (1994) Stratial D2 dopamine receptor characteristics in neuroleptic-naive scizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51(2):116-123
23. Iyo M, Yamasaki T (1993) The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain. Prog Neuro-psychopharmacol Biol Psychiatry 17:415-421
24. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 15:562-566
25. 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology 131:148-152
26. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155(7):921-928
27. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156(2):286-293
28. 2 occupancy, clinical response and side effects: a double blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
29. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
30. Lammerstma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153-158
31. Logan J, Fowler JS, Wolf AP, Fowler JS, Brodie JD, Angrist B, Volkow ND, Gatley SJ (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834-840
32. 2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br bromolisuride. Br J Psychiatry 158:346-350
33. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
34. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152(10):1444-1449
35. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110:265-272
36. 2 receptor occupancy studies and clinical response. Br J Psychiatry 168(suppl 29):40-44
37. Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L (1998) Implication of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13(suppl 3):S15-S20
38. 2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156(6):869-875
39. Okubo Y, Sahara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (2000) Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66 (25):2455-2464
40. Radat F (1995) Cyamemazine:traitement symptomatique desdimensions anxieuses, impulsives et agressives. Inf Psychiatr 10:967-968
41. Reimold M, Mueller-Schauenburg W, Becker GA, Reischl G, Dohmen BM, Bares R (2004) Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves. Eur J Nucl Med Mol Imaging 31(4):564-577
42. Richelson E (1999) Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60(suppl 10):5-14
43. Sedvall G, Pauli S, Farde L, Karlsson P, Nyberg S, Nordström AL (1995). Recent developments in PET scan imaging of neuroreceptors in schizophrenia. Isr J Psychiatry Relat Sci 32(1):22-29
44. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
45. 2A receptors: a PET study of chlorpromazine, clozapine, and amisulpiride in schizophrenic patients. Am J Psychiatry 155:505-508
46. Varga J, Szabo Z (2002) Modified regression model for the Logan plot. J Cereb Blood Flow Metab 22:240-244
47. 18F-N-methylspiroperidol. Psychiatry Res 67:11-16
48. Wang GJ, Volkow ND, Logan J, Fowler JS et al (1995) Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 56(14):249-253
49. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH (2004) Associated alterations of stratial dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161(8):1496-1498